MYBL2 and neoplasm: Despite receiving BCMA/CS1 dual-target CAR-T therapy, the patient's tumor continued to progress, failing to suppress extramedullary relapse, while the poor prognosis was potentially associated with increased MYBL2 expression levels [94].